PathoLase Overview

  • Founded
  • 2004
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Buyout/​LBO
  • Financing Rounds
  • 2

PathoLase General Information

Description

Developer of a new laser procedure that kills the pathogens that cause toenail fungus. The company's therapies are designed for diseases caused by pathogens in bodily cavities, fluids and external infections.

Contact Information

Website
www.uvacide.com
Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Primary Industry
Other Devices and Supplies
Acquirer
NuvoLase
Primary Office
  • 275 Airpark Boulevard
  • Suite 500
  • Chico, CA 95973
  • United States
+1 (530) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PathoLase Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PathoLase‘s full profile, request access.

Request a free trial

PathoLase Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PathoLase Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PathoLase‘s full profile, request access.

Request a free trial